Syndax
  • Home
  • About Us
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Contact Us
Syndax
Contact Us
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • FAQs
    • Contact Us
  • Join Us

Pipeline

Revumenib (SNDX-5613)

Menin Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AUGMENT-101-2A
(monotherapy)
MLLr ALL/MPAL
AUGMENT-101-2B
(monotherapy)
MLLr AML
AUGMENT-101-2C
(monotherapy)
mNPM1 AML
AUGMENT-102
(chemotherapy combination)
MLLr ALL/MPAL/AML,
mNPM1 AML

Axatilimab (SNDX-6352)

CSF-1R mAB
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AGAVE-201
(monotherapy)
Chronic GVHD
SNDX-6352-0503
(monotherapy)
Chronic GVHD

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
Entinostat
Under review

Revumenib (SNDX-5613)

Menin Inhibitor

AUGMENT-101-2A

MLLr ALL/MPAL

Pivotal

AUGMENT-101-2B

MLLr AML

Pivotal

AUGMENT-101-2C

mNPM1 AML

Pivotal

AUGMENT-102

MLLr ALL/MPAL/AML,
mNPM1 AML

Phase 1

Axatilimab (SNDX-6352)

CSF-1R mAB

AGAVE-201

Chronic GVHD

Pivotal

SNDX-6352-0503

Chronic GVHD

Phase 2

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor

Entinostat

Under Review

© 2023 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • Investors
  • Career Opportunities